Urge Incontinence, Urgency-frequency Syndrome
Conditions
Keywords
urgency, urge urinary incontinence, solifenacin, sexual function, menopause, anticholinergic
Brief summary
This study aims to determine whether Solifenacine used for lower urinary tract symptoms improves sexual function and if so does this improvement differs between premenopausal and postmenopausal women.
Detailed description
Solifenacin is an anticholinergic drug that is commonly used for lower urinary tract symptoms such as urgency, frequency and urge urinary incontinence. Solifenacin use and sexual function improvement is presented in some research, but the correlation between the improvement in sexual function and LUTS symptoms is yet not investigated. Also the effect on sexual function in premenopausal vs postmenopausal women are unknown.
Interventions
OTHERno intervention
no intervention planned, since it is an observational study
Sponsors
Arnavutkoy State Hospital
Istanbul University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
* Women presented in Arnavutkoy State Hospital Gynecology Clinic with lower urinary tract symptoms that are planned to start treatment with Solifenacin 5 mg (Vesicare 5mg). * Patients agreed to involve in the study, having discussed other treatment options and possible side effects of the medication. * Informed consent obtained
Exclusion criteria
* urinary tract infection * stress urinary incontinence * urinary retention * grade 2 or above pelvic organ prolapse according to POP-Q scale * Solifenacin contraindications such as narrow angle glaucoma, allergy of Solifenacin or other components of the drug.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| the effect of solifenasin used for lower urinary tract symptoms on sexual function | 6 months | Female Sexual Function Index (FSFI) scores change between in baseline, 3 and 6 months after Solifenacin use for lower urinary tract symptoms. |
| the effect of solifenasin used for lower urinary tract symptoms on sexual function in premenapausal vs postmenapausal women | 6 months | The aim of this study is to determine whether Solifenacine used for lower urinary tract symptoms improve sexual function (measured by Female Sexual Function Index; higher scores meaning sexual dysfunction with the cut off value of 26.) and if so does this improvement differs between premenaupausal and postmenaupausal women. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the effect of Solifenacin treatment for lower urinary tract symptoms (LUTS) on sexual function and its correleation with the improvement in LUTS | 3 and 6 months | The aim of this study is to determine whether Solifenacine used for lower urinary tract symptoms improve sexual function (measured by Female Sexual Function Index; higher scores meaning sexual dysfunction with the cut off value 26.)and if so does this correlates with the improvement with lower urinary tract disorders. |
Countries
Turkey (Türkiye)
Contacts
Primary ContactInci Sema Tas, MD
Outcome results
None listed